INNOVIVE Pharmaceuticals Inc., a biopharmaceutical company headquartered in Manhattan, N.Y., has enrolled the first patients in a Phase I clinical trial of INNO-105 in adult patients with advanced solid malignancies. The objectives of the trial are to determine safety, dose, pharmacokinetic profile and preliminary efficacy of INNO-105.
